Avalo Therapeutics (AVTX) Operating Expenses (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Operating Expenses data on file, last reported at $20.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 42.48% year-over-year to $20.9 million; the trailing twelve-month figure through Mar 2026 stood at $79.2 million (up 55.76% YoY), and the FY2025 full-year result was $73.0 million, up 5.85% from the prior year.
• Operating Expenses for Q1 2026 stood at $20.9 million, up from $19.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $32.8 million in Q1 2024 and bottomed at $4.0 million in Q3 2023.
• The 5-year median for Operating Expenses is $13.1 million (2024), against an average of $14.6 million.
• The widest annual swing landed in 2023, when Operating Expenses sank 63.28%; it then surged 253.59% in 2024.
• A 5-year view of Operating Expenses shows it stood at $9.8 million in 2022, then declined by 15.61% to $8.2 million in 2023, then soared by 64.09% to $13.5 million in 2024, then surged by 46.64% to $19.8 million in 2025, then gained by 5.56% to $20.9 million in 2026.
• The last three Operating Expenses figures came in at $20.9 million (Q1 2026), $19.8 million (Q4 2025), and $19.2 million (Q3 2025), per Business Quant data.

Peer Comparison